Efficacy and safety of a fixed‐dose combination of dapagliflozin and linagliptin ( <scp>AJU</scp> ‐ <scp>A51</scp> ) in patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, parallel‐group, placebo‐controlled phase <scp>III
Dapagliflozin and linagliptin FDC (AJU-A51) showed potent glucose-lowering effects, with good tolerability, in patients with T2D who had poor glycaemic control on metformin and linagliptin (ClinicalTrials.gov [NCT06329674]).
Authors
- Byung‐Wan Lee (ORCID: https://orcid.org/0000-0002-9899-4992)
- Jun Goo Kang (ORCID: https://orcid.org/0000-0001-9523-7251)
- Tae Nyun Kim (ORCID: https://orcid.org/0000-0001-6568-2469)
- Woo Je Lee (ORCID: https://orcid.org/0000-0002-9605-9693)
- Myeong‐Jin Kim (ORCID: https://orcid.org/0000-0001-7949-5402)
- Jong Chul Won (ORCID: https://orcid.org/0000-0002-2219-4083)
- Chang Beom Lee (ORCID: https://orcid.org/0000-0003-4891-834X)
- Ho Sang Shon (ORCID: https://orcid.org/0000-0002-7443-9206)
- Bon Jeong Ku (ORCID: https://orcid.org/0000-0002-3414-8949)
- Jae Hyeon Kim (ORCID: https://orcid.org/0000-0001-5001-963X)
- Jung Hwan Park (ORCID: https://orcid.org/0000-0002-8737-0084)
- Sang Yong Kim (ORCID: https://orcid.org/0000-0001-7326-7505)
- Kyung Wan Min
- Jun Hwa Hong
Institutions
- Inje University (KR)
- Ulsan College (KR)
- Yonsei University (KR)
- Chungnam National University (KR)
- Eulji University (KR)
- Asan Medical Center (KR)
- Samsung Medical Center (KR)
- Daegu Catholic University (KR)
- University of Ulsan (KR)
- Chosun University Hospital (KR)
- Inje University Sanggye Paik Hospital (KR)
- Hanyang University Guri Hospital (KR)
- Hallym University Sacred Heart Hospital (KR)
- Hanyang University (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1111/dom.15985
- Citations
- 5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.79